Alexey Boronenkov, one of the clients of the company Kriorus, frozen brain and my 70 year old mother in the hope that it will be able to return to life with the help of scientific progress.

I took this decision because we were very close. I thought that this is the only opportunity to meet in the future, he said.

He himself is going to cryonization after death.

I Hope one day we will reach such a level that it will be possible to create an artificial body with an artificial muscle tissues and organs which may be transplanted the brain of my mother, he says.

the ContextHoliness and frozen Ilta-Sanomat18.01.2018 Stern: the Russian business aimed at Stern03.10.2018 Cryopreservation as a successful Helsingin Sanomat11.06.2017

investing in the future for tens of thousands of dollars

In the suburban tanks of the company in liquid nitrogen at minus 196 degrees stored the body or the brain 71 people and Pets. It is an expensive procedure. The preservation of the whole body will cost 36 thousand dollars, the preservation of the brain 15 thousand dollars.

This is a much higher level of average salaries of Russians. For foreigners the cost is a little higher. Customers from more than 20 countries have signed a contract with the company regarding further actions with their bodies after death.

a Firm referred to as expensive funeral Agency

the activity of the company is often criticized. Evgeny Alexandrov, the head of the Commission of Sciences to combat pseudoscience and falsification of scientific data, said the newspaper FStia that cryonics is a very commercial idea that lacks any scientific basis.

Its a fantasy, speculating on the hopes of the people about the resurrection of the dead and dreams of eternal life quoted by his newspaper.

Valeria Udalova Director of the company, her dead dog froze in 2008. She considers it likely that humanity will be able to develop the technology to revive dead people. However, she acknowledges that no guarantees for this.

According to Valerie Udalovoy, the people who pay for the procedure for preservation of bodies of relatives show how much they love their loved ones.

They need hope, she says.

What can we do for our dead relatives and loved ones? A good funeral, an album of photographs. And these people go on proving their love even stronger.

the new York times contain estimates of the solely foreign media and do not reflect the views of the editorial Board of the new York times.

Read the original post:
MTV (Finland): the Russian firm will freeze your body or brain for resurrection in the future - International Law Lawyer News

Recommendation and review posted by Bethany Smith

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development.(iStock)

Hair loss is typically considered the domain of aging men, but this equal-opportunity condition which has many causes can affect virtually anyone.

Alopecia is the medical term for hair loss, and it doesnt only happen on the scalp. Some illnesses and medications can trigger balding over the entire body, though genetics account for most cases on the head, according to theCleveland Clinic.

PARTY DRUG MDMA A STEP CLOSER TO LEGALIZATION FOR PTSD THERAPY

Everyone sheds about 100 hairs each day as part of the normal hair growth cycle, but excess loss is usually a distressing development. Americans spend more than $3.5 billion each year trying to treat it, according to theAmerican Hair Loss Association.

Most peoples hair grows about a half-inch per month, and about 90 percentof your hair is actively growing at any given time, with the other 10 percentin dormant phase. After two or three months, this dormant hair falls out and its follicles begin growing new hair as other follicles begin a dormant phase.

Shedding hair is different from hair loss, when a hair falls out and doesnt grow back. People often shed hair during stressful events, such aschildbirth, a breakup or divorce or during times of grief.

It still doesnt feel good, and it takes the hair [awhile] to reach a certain length where you perceive its presence, said Doris Day, a board-certified dermatologist New York City and an attending physician at Lenox Hill Hospital, also in New York. So it feels like a hair loss, but its not a hair loss.

Aside from heredity, noticeable hair loss can be caused by wide variety of factors, including:

Harsh hairstyles or treatments: Hairstyles that consistently use rubber bands, rollers or barrettes, or pull hair into tight styles such as cornrows, can inflame and scar hair follicles. So can incorrectly used chemical products such as dyes, bleaches, straighteners or permanent wave solutions. Depending on the degree of damage, resulting hair loss can be permanent.

Hormone imbalances: In women, hormonal shifts from birth control pills,pregnancy, childbirth, menopause or hysterectomy can induce more hair follicles than normal to enter the dormant phase.

Illness or surgery: The stress from sickness or surgery may prompt the body to temporarily cease nonessential tasks such as hair production. Specific conditions can also trigger it, including thyroid disorders,syphilis, iron deficiency,lupusor severe infection. An autoimmune condition called alopecia areata, which has no cure, causes rapid body-wide hair loss.

Medications and vitamins: Cancer chemotherapy, which attacks hair follicles in its attempt to kill all fast-growing cells around the body, is a well-known reason for hair loss. Other medications side effects include hair shedding as well, such as some that treat high blood pressure andgout(a painful joint condition caused by a buildup of uric acid). Excessive levels of vitamin A also contribute.

Nutritional deficits: Heavy dieting or eating disorders such asbulimiaandanorexiacan temporarily stun hair follicles to cease growth. This can also occur from insufficient protein, vitamin or mineral intake.

Aging: A natural effect of growing older is slowed hair growth.

Women usually dont go completely bald, but lose hair on the top of the head or the temples. Men tend to lose hair on their temples, and are more likely than women to go completely bald, Day said.

Dermatologists will examine the persons scalp and take a history of medical or stressful events to see whats been going on in their life and their world, Day said.

HELICOPTER-SHARING APP BLADE PAIRS WITH NYU LANGONE TO SPEED TRANSPLANT ORGANS

The dermatologist may take a biopsy a small patch of skin that includes the hair follicle and send it to a pathologist to determine if an autoimmune disease, such as lupus, is the cause of the hair loss.

Examining the hair and follicle can also determine whether someone has a bacterial or fungal infection, Day said.

Hair loss remedies range from the mild to the extreme and the inexpensive to the costly. Much depends on how much hair is gone and how high a priority it is to mask its absence or replace it.

According to the Cleveland Clinic, treatments include:

Hair weaves or wigs: Typically expensive, wigs and hair weaves either completely cover the head or add to existing hair, restoring the appearance of a full head of hair. They are especially practical for cancer patients and those whose hair loss is temporary.

Topical creams and lotions: Over-the-counter minoxidil (also known as the brand name Rogaine) can restore some hair growth, especially in those with hereditary hair loss. It is applied directly to the scalp. Prescription-strength finasteride (Propecia) comes in pill form and is only for men. According to theAmerican Academy of Family Physicians(AFP), it may take up to six months to tell if these medications are working.

Anti-inflammatory medications: Prescription steroid-based creams or injections can calm follicles damaged or inflamed by harsh chemicals or excessive pulling.

Surgery: Men tend to be better candidates for surgical hair-replacement techniques because their hair loss is often limited to one or two areas of the scalp. Procedures include grafting, which transplants from one to 15 hairs per disc-shaped graft to other locations. Scalp reduction removes bald skin from the scalp so hair-covered scalp can be stretched to fill in the bald areas. Side effects include swelling, bruising and headaches.

Hair-growth laser treatment can also help stimulate hair follicles and improve growth, Day said. People often see results when they combine laser treatment with another intervention, she said. Treatments range in price from $30 and up for Rogaine to about $3,000 for laser treatment, she added.

According to theNational Institute of Arthritis and Musculoskeletal and Skin Diseases(NIAMSD), alternative therapies may not help hair regrow and many are not supported by medical research. However, other treatments that reportedly improve alopecia areata include Chinese herbs, acupuncture, zinc and vitamin supplements, evening primrose oil and aroma therapy.

Viviscal, a natural supplement, has also shownmore hair growthin men compared to those who took fish extract in clinical trials, Day said.

The NIAMSD recommends discussing any alternative treatments with physicians before use.

The drug Tofacitinib is approved to treat adults witharthritis, but a growing number of cases suggest that it can also treat alopecia universalis, a condition in which people lose all of the hair on their body because theirimmune systemattacks hair follicles,Live Science previously reported.

The finding occurred after doctors prescribed a 25-year-old man with alopecia universalis the drug because they had heard it had treated a similar condition in mice,according to a statement from Yale University. After three months of treatment, the man had completely regrown the hair on his scalp, and he had visible eyebrows, eyelashes, facial hair, as well as hair elsewhere on his body.

Its exciting, said Day, who did not treat this particular patient. There seems to be a real effect here.

CLICK HERE TO GET THE FOX NEWS APP

Its unclear how Tofacitinib (brand name Xeljanz) works, but researchers hope to determine its mechanism soon. This data may help them learn which biological pathways lead to hair loss.

There are now clinical trials taking place around the country to test the safety and efficacy of the drug for hair loss conditions. One such study lasting 3 months gave Tofacitinib to 66 people with alopecia areata (an immune system condition that causes hair to fall out in patches). Half of the people regrew some hair, and one-third had more than 50 percentof the hair on their scalp grow back, according to the 2016 study, published in the journalJCI Insight.

However, researchers are still working to determine the best dose needed, whether the results are lasting, and whether they can develop a topical form of the drug, Day said. She added that patients should be aware that Tofacitinib has side effects. Its already associated with an increased risk of serious infections, as well as stomach and intestinal tears, according to Pfizer, the manufacturer.

Besides investigating Tofacitinib, researchers are also looking at ways to clone hair or use stem cell therapy to treat alopecia, Day said.

This article first appeared on LiveScience.

Originally posted here:
Alopecia: What causes the hair loss condition? - Home - WSFX

Recommendation and review posted by Bethany Smith

Photo: Kohei Hara/Getty Images

Like everyone else, I wonder all the time: Why am I always tired? But sometime last fall, I started getting extra droopy every afternoon. Even when Id done all the right things slept eight hours, eaten a healthy lunch, exercised Id be fighting to keep my eyes open by 4 p.m. On one of those days, as I waged war against my thousand-pound eyelids, a friend started complaining to me about her new glasses, which shed been forced to buy because contact lenses irritated her eyeballs in the dry winter air. As a fellow contact-lens wearer, I realized that perhaps my 4 p.m. sleepiness problem wasnt that I was tired maybe my eyes were. When I tested my theory and used Visine drops in the afternoons, my midday nap attacks went away.

Of course, most fatigue problems arent so easily solvable. Even the simplest fix to sleep more can be hard to come by, especially when theres an underlying problem in the mix. Unfortunately, most tiredness feels about the same; Lyme disease doesnt really give you a different flavor of exhaustion than, say, an iron deficiency or garden-variety night of tossing and turning. But if you look at other symptoms accompanying your fatigue, you might find clues to where its coming from.

If your tiredness is chronic and inexplicable or just feels off you should consult a doctor, as it could be a red flag for something more serious. And either way, its a problem you should be able to solve. To understand more about the different types of fatigue, I spoke to Dr. Jaclyn Tolentino, a primary care physician at Parsley Health, as well as Dr. Richard Firshein, a general practitioner and insomnia specialist who runs the Firshein Center in Manhattan. Here are the most common culprits of exhaustion, and how to treat them.

Hormone fluctuations can turn anyone into a nap machine, as anyone whos ever had PMS knows. But chronic hormonal imbalances can make you sleepy and grumpy all month long. The good news is that doctors can test for the presence of most hormones, so they should be able to diagnose an imbalance if you have one; most are also largely treatable with medication and/or nutritional changes. One common issue is underproduction of estrogen or progesterone, which can cause tiredness, irritability, unpredictable periods, and night sweats. (If you wake up feeling like youve just run a marathon in your pajamas, this could be your issue.)

Other hormones that can disrupt your sleep if they get out of whack are melatonin and cortisol, which are produced by your pituitary glands. You can get supplements of the former from almost any drugstore, but Dr. Tolentino recommends taking no more than 3 milligrams. The amount of melatonin your body produces is tiny compared to the melatonin supplements you can buy, so most people are actually taking much more than the body needs or should have, making the imbalance worse, she says. In other words, taking melatonin supplements to help you sleep at night could actually be contributing to your overall tiredness during the day the irony, I know!

If your tiredness coincides with weight gain, dry skin, and constantly feeling cold, you could be having issues with your thyroid, which produces hormones that regulate your metabolism, among other things. Hypothyroidism is one of the most common conditions associated with fatigue, says Dr. Tolentino. Other symptoms of hypothyroidism include constipation, hair loss, and irregular menstrual cycles. If youre experiencing any of these symptoms, its best to consult a doctor as soon as possible.

Take it from someone whos frequently anemic no matter how much steak I eat: The tricky part of getting enough vitamins and minerals is that certain nutrients are essential for the absorption of others so if you arent getting enough of one, then youre probably missing out on a bunch. Common deficiencies that cause fatigue include iron, magnesium (which contributes to the bodys absorption of iron as well as other nutrients), B vitamins, and vitamin D (which your body produces when its exposed to sunlight which doesnt happen much in the winter). Your doctor can test for all of the above, but for what its worth, Ive been taking magnesium powder every night before bed for the past six months, and it has made a huge difference in how I feel every morning. Dr. Tolentino says she recommends it to many of her patients, because it binds to melatonin and supports its production in your body.

You cant sleep because youre staring at the ceiling, ticking through all the things you messed up that day and didnt get done, and now youre extra stressed because youre stressed, and if you dont get to sleep soon then youll be even more stressed tomorrow, and blah blah stress is bad and we all need to manage it better. But in addition to making you miserable and annoying, chronic stress actually causes the overproduction of cortisol (see No. 1), a hormone that disrupts sleep. Ignore the problem and it spirals, causing weight gain, more sleeplessness, and a whole host of other issues.

You know what youre supposed to do for stress: Take breaks. Exercise. Cultivate supportive relationships. Meditate. And get enough sleep. But those things take time and energy, which seem in short supply when youre dealing with a firestorm at work (or just normal life). Dr. Firshein recommends what he calls mini-meditations, which he practices himself. Its a huge luxury to be able to set aside 30 minutes or an hour to meditate, but if you take just a few moments throughout the day, it can have a similar effect, he says. In between every patient, I take ten or 20 seconds to breathe deeply, do some visual imagery, and relax my muscles before I move on. By the end of the day, it adds up to 15 or 20 minutes of meditation. He urges patients to do the same every time they check their phone, for example, or get a text from a certain person, or get up from their desk at work. If you reset your mind consistently throughout the day, then it can keep anxiety from sneaking up on you.

Its true: Certain genes have been linked to chronic fatigue issues, including a specific one known as the CLOCK gene (yep), which is linked to faulty circadian rhythms. People with wonky CLOCK genes have issues with their metabolism, body temperature, blood pressure, and liver functions, among others. Luckily, its very rare.

A more common genetic mutation that could disrupt your sleep is one that affects your bodys ability to process alcohol, says Dr. Firstein. Alcohol causes a lot of sleep problems in itself, but some people are predisposed to be even more sensitive to it.

A doctor can test for these genes, although it can be expensive to do so and insurance may not cover the lab costs. Before you go down that rabbit hole, look at your family history do any of your relatives have similar bad reactions to alcohol, or other symptoms of the CLOCK gene? While you cant change your own genetic makeup, identifying a genetic issue can help you and your doctor come up with a plan to treat the problems that stem from it.

Speaking of alcohol and sugar, caffeine, your phone, your laptop, your TV screen, your neighbors music, your roommates music, LED lighting, your newborn kid, or the fries you just ate, you are surrounded by things that cause you to sleep poorly and be tired the next day. Both Dr. Firshein and Dr. Tolentino said that lifestyle is usually the No. 1 cause of tiredness, but the good news is that you can do something about it.

Weve become a little bit lazy around sleep, says Dr. Firshein. Good sleep hygiene begins hours before you actually go to bed. It takes discipline to power down at the end of the day, turn off the TV and the computer, and cut back on external light, noise and stimulus. If youre not able to do all that (because, come on), he recommends at least wearing blue-light-blocking glasses, dimming the lights, and not eating or exercising within two to three hours of bedtime.

And finally, pony up the $20 to buy an actual alarm clock and put your phone in another room before you go to bed. Ive personally found this helpful not only for falling and staying asleep, but also for getting out of bed in the morning. Instead of snoozing my phone a million times and then lazing around scrolling through garbage, I actually get up and brush my teeth and start my day after my alarm goes off, for the most part. One other tip: I sleep with a white noise machine and earplugs. (I live next to a fire station, so.)

Does your bedmate frequently shove you in the middle of the night to get you to pipe down? Do you have allergies or get a lot of sinus infections? You might have sleep apnea, a deviated septum, or another issue that inhibits your breathing and stops you from getting the kind of deep sleep that makes you feel truly rested. There are various solutions for these problems, ranging from special breathing machines to surgery; youll want to consult a doctor if you suspect you fall into this camp.

Hopefully not! But fatigue is often the most obvious symptom of autoimmune conditions like lupus, fibromyalgia, and Hashimotos thyroiditis, says Dr. Tolentino. The same goes for chronic infections like Lyme disease. Often these conditions are accompanied by other symptoms. But just like with sleep apnea, dont waste time trying to self-diagnose and get to a doctor.

Get the Cut newsletter delivered daily

More here:
What Kind of Tired Are You? - The Cut

Recommendation and review posted by Bethany Smith

High school and college athletes in Kentucky would only be allowed to compete in sports that align with their biological sexand not their preferred gender identityunder a bill that a state lawmaker filed Friday.

Sen. Robby Mills, R-Henderson, introduced Senate Bill 114 and titled it the "Save Womens Sports Act."

The bill calls for students to only participate in sports and use athletic facilities that correspond with the sex listed on their birth certificates.

If astudent's birth certificate has been edited or if the student's biological sex is officially challenged, then the student would have to undergo a medical examination performed and signed by a physician, physician's assistant or advanced practice registered nurse.

The examination would establish the student's sex based solely on "internal and external reproductive anatomy," testosterone levels and an "analysis of the student's genetic makeup," according to the bill.

Mills could not immediately be reached for comment.

More: Lawsuit: Louisville Christian school,conservative writerouted 'rainbow cake girl'

SB 114 would allow students who have been "deprived of an athletic opportunity" or who have suffered "any direct or indirect harm" or privacy violations due to violations of the bill's regulations to school districts and universities within two years "after the harm occurred."

Chris Hartman, executive director of the Louisville-based Fairness Campaign, an LGBTQ advocacy organization, said the bill is "once again a solution in search of a problem" and "a plea for votes in an election year."

"This is clearly part of a politically motivated (and)expanding slate of hate that's being introduced in the state targeting all LGBTQ people but with particular emphasis on transgender students," Hartman said. "...Imagine how hard it is for trans kids already on a daily basis. This bill tells them they shouldn't be participating in athletics."

"Transgender kids want to join sports teams for all the same reasons any other student does," Hartmanadded.

The Kentucky High School Athletic Association currently has a policy that recognizes the ability of transgender student-athletes to compete in sports "free from unlawful discrimination based on sexual orientation."

But some still view the KHSAA policy as restrictive, as it requires transgender athletes to undergo sex reassignment surgeryeither before or after puberty inorder to compete in sports based on their gender identity.

If reassignment surgery occurs after puberty, then transgender student-athletes in Kentucky must demonstrate that they've taken or are taking hormone therapy "for a sufficient length of time to minimize gender-related advantages in sports competition," according to the KHSAA policy.

As The Courier Journal reported last year, Kentucky was one of nine states with such policies for transgender high school athletes.

Southern Pride:LGBTQ athletes in Kentucky face challenges as an 'invisible minority'

Hartman said "few, if any" transgender students can currently meet the KHSAA guidelines, making Mills'bill unnecessary.

"I guarantee that Sen. Mills doesn't have a single instance in Kentucky athletics that this bill would address, not a single one," Hartman said. "If he can bring a witness to the table whom this applies to...I'd be shocked."

The topic of transgender athletesin Kentucky came up during the 2019 gubernatorial race between DemocratAndy Beshear and then-Republican Gov. Matt Bevin when aconservative political action committee released an ad claiming Kentucky boys are changing their gender to participate in high school sports.

The ad from the Virginia-based Campaign for American Principlesfeatured a narrator saying that Beshear the state's attorney general at the timewho is now governor after beating Bevin in November's election "supports legislation that would destroy girls' sports."

It showed a male competitor portraying a transgender girl and passinga group of female runners tofinishfirst.

The new proposal from Mills related to high school and college athletes is not the only bill in the 2020 legislative session that deals with transgender students.

House Bill 132 would bartransgender students from usingrestrooms that alignwith their gender identities.

State Rep. David Hale, R-Wellington, is the lead sponsor of the bill, which is titled the "Kentucky Student Privacy Act"and says non-transgender students could suffer"potential embarrassment, shame and psychologicalinjury" by using the same restroom or changing room as their transgender peers.

LGBTQ advocates have called Hale's bill "dangerous" and warned it would contribute to depression and suicide rates among transgender youth.

A similar bill has been introduced inpast General Assembly sessions, including one proposal in 2015 that would have allowedstudents to sue aschool for $2,500 ifthey encountered a person of the opposite biological sex in a bathroom or locker room and staff hadallowed it or failed to prohibit it.

State Sen. C.B. Embry Jr., R-Morgantown, proposed the2015 version of the "Kentucky Student Privacy Act" in response to a 2014 controversy at Louisville's Atherton High School in which the principal allowed a transgender student who was born male but identifies as a female to use the girls' bathrooms and locker rooms.

A bipartisan group of Kentucky lawmakers are also behind a push to ban conversion therapy in the Bluegrass State.

On Politics:Can conversion therapy ban pass if top Kentucky lawmakers don't understand it?

This story may be updated.

Reach Billy Kobin at bkobin@courierjournal.com or 502-582-7030. Support strong local journalism by subscribing today: courier-journal.com/subscribe.

Read or Share this story: https://www.courier-journal.com/story/news/politics/ky-general-assembly/2020/01/25/kentucky-bill-would-require-athletes-compete-based-sex-birth-not-gender-identity/4575196002/

Go here to read the rest:
Kentucky bill would require athletes to compete based on sex at birth - Courier Journal

Recommendation and review posted by Bethany Smith

]]> Royal Tank Regiment upgraded Challenger 2s. Credits: Elbit Systems UK. Sign-up to the Army Technology newsletter

The upgrade, which delivers an urbanised Challenger 2 variant, was developed by the Royal Tank Regiment to meet soldiers needs and identifies and fills the capability gap between the British Armys forces and adversaries in urban combat.

Supported by Army HQ, project Streetfighter II is aimed at adding modifications to the existing Challenger II Main Battle Tank (MBT) to improve lethality, situational awareness and infantry-tank cooperation of ground forces.

The vehicle was recently trialled at the UKs urban operations facility at Copehill Down Village on Salisbury Plain, where the Streetfighter was put through its paces in an urban combat environment testing a range of upgrades from industry partners.

This year Streetfighter demo built on earlier experience of the project that began in 2018 and saw the upgrades showcased to a range of senior military figures and officials from the Defence Science Technology Laboratory (Dstl).

The Streetfighter II MBT demonstrated by the British Army featured a range of lethality upgrades including heavier, more lethal machine gun systems to provide dismounted infantry better support fire.

The most notable upgrade was one of the two urbanised Challengers being equipped with a Brimstone anti-tank guided missile system designed to neutralise the threat of heavily armoured, highly survivable land platforms at long-range.

The Brimstone, made by MBDA, is designed to destroy fast-moving vehicles alongside tanks and other lighter-armoured vehicles as well as fixed positions like bunkers and can be fired from a range of platforms.

On the situational awareness front, the Streetfighter concept greatly improves the ability of mounted and dismounted personnel to communicate and understand their environment, with communications improved to let personnel on the ground directly communicate with those inside the tank.

The upgraded Challenger features a host of cameras to provide a 360-degree view of the area outside the tank; the original Challenger 2 has a limited field of view and the upgrades mean the commander and gunner can now see everything around them.

The Streetfighter II variant also features a barrel-mounted camera to enable the tank commander and crew to see around corners before they approach them, alerting them and the following personnel in advance of any previously hidden threats.

A major situational awareness upgrade comes in the form of Elbit Systems UKs IronVision platform which uses a heads-up-display (HUD) to provide tank crews with full 360 situational awareness.

The zero-latency system allows the crew to have a full picture of their operating environment despite being under armour by feeding in a picture from outside the tank into the HUD.

Elbit Systems UK CEO Martin Fausset said: It is great to see Elbit Systems UK supporting the UK Armed Forces as they enhance their battlefield protection systems for urban environments. We relish the opportunity to protect our servicemen and women in the field and are pleased to see the IronVision system delivering in this capacity.

IronVision pulls together the feeds from the various cameras outside the MBT and then converts them into a single picture where the tank operator only needs to turn their head to see a different view of outside the vehicle, rather than cycle through cameras on a screen.

Elbits IronVision system. Credits Elbit Systems UK.

On the slightly more low-tech front, the MBT also supports infantry by physically lightening the load on personnel by carrying extra gear from medical equipment to ammunition, and the addition of a storage rack to carry an urban assault kit.

The improved Challenger 2 is also fitted with steps built into the side of the vehicle allowing personnel to mount and dismount the platform more easily. One of the tanks is also fitted with a plough to clear obstructions from the urban environment allowing personnel to continue moving forward and acting as a makeshift stretcher to transport injured personnel out of the combat environment.

It is unclear whether the upgrades made by the Royal Tank Regiment will be employed across the wider fleet of Challenger 2 vehicles. However, in the British Armys wider plans for tanks, the life-extension programme continues to be a priority, in order to continue the service life of the vehicle and maintain the ability of the UK to deploy MBTs into battle.

Current plans for the Challenger 2 life extension programme are slowly drawing to a close after first being tabled in 2013. Any decision on the future of the Challenger 3 will now likely become wrapped up in the planned UK Strategic Defence and Security Review (SDSR) which will look at the needs of the Armed Forces and help guide their future shape.

At Defence IQs International Armoured Vehicles 2020, British Army director capability, Major General Jez Bennett reaffirmed the commitment to the vehicle and outlined the scope of the current life extension programme.

Bennet said: The Challenger 2 programme aims to deliver an enhanced main battle tank, with greater lethality and survivability that will provide precision direct fire and intimate support to the infantry until well into the next decade.

Read the original here:
Streetfighter and the future of the Challenger 2 - Army Technology

Recommendation and review posted by Bethany Smith

In another sign that the nuclear arms race is heating up, the U.S. is ramping up production of nuclear bomb cores.

The National Nuclear Security Administration (NNSA) has announced that it plans to increase theproduction of plutonium pits to 80 per year. The grapefruit-sized pits contain the fissile material that give nuclear weapons such tremendous power.

Production will center on the Mixed-Oxide Fuel Fabrication Facility at Savannah River site in North Carolina, which would be modified to manufacture at least 50 pits per year, and Los Alamos National Laboratory in New Mexico, which would generate at least 30, by 2030.

Americas nuclear weapons cores are aging, with some pits dating back to the 1970s, leading to concerns about the reliability of the U.S. nuclear stockpile.

The U.S. lost its ability to produce pits in large numbers in 1989, when the Rocky Flats Plant near Denver, Colorado, was shut down after the Federal Bureau of Investigation and Environmental Protection Agency investigated environmental violations at the site, noted Physics Today magazine in 2018. Up to 1,200 pits per year had been manufactured there.

Since then, only 30 pits for weapons have been fabricatedall at LANL [Los Alamos National Laboratory], the sole U.S. facility with production capability. Weapons-quality pit production ceased in 2012, when LANL began modernizing its 40-year-old facilities, although several practice pits have since been fabricated. The oldest pits in the stockpilewhich now numbers 3,882, according to DOEs National Nuclear Security Administration (NNSA)date to 1978.

In its 2018 Nuclear Policy Review, the Trump administration called for 80 new plutonium pits per year. Congress has also allocated large sums, with $4.7 billion alone allocated in FY 2019 for maintenance and life extension of the nuclear stockpile. The NNSA says it is legally mandated to ensure a capacity of at least 80 pits per year.

Though the production of nuclear cores has been an issue for years, a looming U.S.-Russia arms race makes the situation even more sensitive. Russia is fielding a new generation of strategic nuclear weapons, including a hypersonic nuclear-armed glider and an air-launched ballistic missile. The Trump administration has withdrawn from the 1987 Intermediate-Range Nuclear Forces treaty with Russia, alleging Russian violations, leading to fears that a new competition will beget the return of nuclear-armed, medium-range ballistic and cruise missiles.

Anti-nuclear groups are furious. Expanded pit production will cost at least $43 billion over the next 30 years, argues the Natural Resources Defense Council and other groups. Yet the Defense Department and NNSA have never explained why expanded plutonium pit production is necessary. More than 15,000 plutonium pits are stored at NNSAs Pantex Plant near Amarillo, Texas. Independent experts have concluded that plutonium pits have reliable lifetimes of at least 100 years (the average pit age is less than 40 years). Crucially, there is no pit production scheduled to maintain the safety and reliability of the existing nuclear weapons stockpile. Instead, proposed future pit production is for speculative new-design nuclear weapons, but those designs have been canceled.

Introducing a new generation of nuclear weapons could adversely impact national security because newly produced plutonium pits cannot be full-scale tested without violating the global nuclear weapons testing moratorium.

Michael Peck is a contributing writer for the National Interest. He can be found on Twitter and Facebook.

See the article here:
The U.S. is Boosting Production of Nuclear Bomb Cores (For More Nuclear Weapons) - The National Interest Online

Recommendation and review posted by Bethany Smith

Key point:America's F-16 has lasted a long time and has been given many upgrades. However, the F-16 might not be as good against the very best that Beijing and Moscow can throw at it.

You May Also Like: 5 Best Submarines of All Time, 5 Best Aircraft Carriers of All Time, 5 Best Battleships of All Time and Worst Submarine of All Time.

The F-16 fighter was originally conceived as a lightweight fighter for the United States and her NATO allies. In the U.S. Air Force, the Fighting Falcon would comprise the low end of a high-low mix of super-capable F-15s and cheaper, less capable F-16s. Among NATO allies, it would be a frontline fighter to replace aging planes like the F-104 and F-15.

Inevitably, the capable little single-engine fighter was pushed towards a more diverse array of missions. Originally conceived as just carrying short-ranged AIM-9 Sidewinder missiles, it gained the ability to launch the beyond visual range AIM-7 Sparrow and AIM-120 AMRAAM. Over time it gradually evolved into a versatile air-to-ground platform with the ability to accomplish close air support, battlefield air interdiction and air defense suppression missions with a variety of precision-guided missiles, including the AGM-65 Maverick missile, AGM-88 HARM anti-radar missile and Joint Directed Attack Munition precision-guided bomb.

A confluence of eventsincluding a series of budget-draining wars in the Middle East for which the F-16 has been good enough and delays in the F-35 Joint Strike Fighter programhave conspired to keep the F-16 flying much longer than originally intended. Why the F-16 is still in service is fodder for another article, but the bottom line is that it is serving today and is seriously outmatched by a new generation of Russian and Chinese fighters.

First, lets look at one of the most recent and popular versions of the F-16, the Block 50 variant. Block 50 features a AN/APG-68 V(5) radar, F100-PW-229 afterburning turbofan engine, and the AN/ALE-47 threat adaptive countermeasure system. The Block 50 has a maximum sustained speed of Mach 1.89, a range of 360 miles on internal fuel, and a ceiling described as above 50,000 feet. It can carry up to six AIM-9 Sidewinder short-range infrared homing missiles or six AIM-120 AMRAAM beyond-visual-range missiles, or some combination of either.

Despite the F-16s longevity, obsolescence was inevitable. The F-16 will not fare well against a powerful new generation of Russian and Chinese fighters. The Moscows Su-35 Flanker and PAK-FA fighter and the Beijings J-20 stealth fighter, all previously described here, have rendered the Fighting Falcon obsolete.

Although based on an contemporary of the F-16, the original Su-27 Flanker, the Su-35 has been more thoroughly updated than the spunky American fighter. The Su-35 may not be stealthy, but it can detect and engage the F-16 before the F-16 can detect it, and this puts the American plane at a big disadvantage. In a one-on-one fight, the F-16 will probably not even be able to get the Su-35 into dogfighting range, where the smaller fighters legendary maneuverability would come into play.

The new Russian PAK-FA and Chinese J-20 fighters will have similar advantages, except their stealthy design will ultimately mean F-16s wont even detect their adversaries before they realize they are being targeted by beyond-visual-range guided missiles, launched by aircraft that only visible on radar for the brief moment their internal weapons bay doors are open.

What could be done to give the F-16 better odds? The latest variant of the Fighting Falcon, the F-16V, will have the APG-83 Scalable Agile Beam Radar (SABR) radar, the first AESA radar retrofitted into the platform. SABR has been described as fifth-generation fighter technology, and indeed promises earlier detection, tracking and identification of targets sooner than older radars. The Republic of China Air Forces F-16s will be the first to be brought up to -V standard. The U.S. Air Force is pondering a service life extension program (SLEP) for select aircraft in the F-16C fleet, and the SABR radar is an obvious candidate for inclusion.

Yet improving the F-16s detection ability is only half the problem. While stealth has its disadvantages and countermeasures are inevitable, its also true that, like radar and electronic countermeasures, stealth is now permanently part of the essential feature set of modern combat aircraft. While China and Russia tout new anti-stealth measures, they are also making certain their own new aircraft are as stealthy as possible. That both countries, struggling to catch up with the United States, are still willing spend on stealth is a ringing endorsement of its value.

While SABR will likely improve the F-16s ability to detect fifth-generation fighters such as PAK-FA and the J-20, it will still be easy for enemy aircraft to detect. The F-16s lack of stealth is not something that can be addressed with upgrades to the airframe or an electronics package. The only solution is a new aircraft.

The F-16 still has a great deal of value against smaller, less technologically advanced air forces and air defenses, as well as low- to mid-intensity conflicts such as Libya and Syria. Its also useful as a bomb truck, carrying long-range munitions such as the JASSM cruise missile behind a protective wall of F-22 and F-35 fighters. But thanks to PAK-FA and the J-20, its days as a day-one frontline fighter are over. As the F-35 enters service with the United States and with its NATO and Asian allies, the F-16 begins its long, well-earned flight into the sunset.

Also From TNI: Donald Trump: The Worst President Ever?

Also From TNI: Donald Trump: Best President Ever?

Also From TNI: Why Japan Really Lost Pearl Harbor

Also From TNI: What Happens if North Korea Nuked Washington?

Kyle Mizokami is a defense and national security writer based in San Francisco who has appeared in the Diplomat, Foreign Policy, War is Boring and the Daily Beast. In 2009 he cofounded the defense and security blog Japan Security Watch. You can follow him on Twitter: @KyleMizokami. This first appeared in September 2016.

Image: Reuters.

Link:
How Does the Air Force's F-16 Stack up Against the Best Chinese and Russian Fighters? - The National Interest Online

Recommendation and review posted by Bethany Smith

Blue AgaveMarkethas been provided in the latest report launched by Market.usthat primarily focuses on the World industrytrends, demand, Share, Consumption and Growth and Future Forecast 2020-2029.

The report begins with a brief introduction regarding the major factors influencing theBlue Agave Marketcurrent and future growth, challenges, and opportunities, restraints, and trends. The Blue Agave market purpose of the report is to define the market requirements by describing the market information, dynamics, business plans, and segmentation. The researchers provide a detailed study of important parameters for top players including current development, gross margin, market share, future development strategies, product collection, product, and revenue.

Get Exclusively Free Sample Of This Report in PDF @https://foodnbeveragesmarket.com/report/blue-agave-market/request-sample

[Note:Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology]

The report includes an in-depth analysis of the vendor landscape and total business profiling of leading players(Nutragreen Biotechnology, Carruba, Futureceuticals, Bio Botanica, Life Extension, Mazza Innovation) of the Blue Agave Market. This research could help players to identify profit-making opportunities available in the Blue Agave Market. The study presents details on the market share which each country estimates for, as well as the effective growth opportunities expected for each geography. The reports implementing complete analytical data on the geographical segments, which includeNorth America, Europe, and Asia-Pacific, South America, Middle East, and Africa.

On the basis of product,Blue Agave Market report presents size, revenue, product cost, market share and growth rate of each type:

LiquidPowder

On the basis of the end users/applications,Blue Agave Market report concentrates on the status and opportunity for major applications/end users:

PharmaceuticalsFood and BeveragesNutraceuticalsCosmetics and Skin CareOthers

Geographic Coverage And Analysis(Regional Production Growth by 2020, World Approaching Demandand Forecast by Countries etc.):

The Middle East and Africa (GCC Countries and Egypt)

North America (USA, Mexico, and Canada)

South America (Brazil etc.)

Europe (UK, Italy, France, Turkey, Germany, Russia, etc.)

Asia-Pacific (Philippines, Korea, Thailand, Vietnam, China, Malaysia, Japan, India, Indonesia, and Australia)

Place An Inquiry Before Investment (Use Corporate Details Only):https://foodnbeveragesmarket.com/report/blue-agave-market/#inquiry

Highlights of This Report:

1. The report offers a brief analysis of the Blue Agave Market

2. In-depth information about the emerging segments as well as regional Blue Agave Market

3. To analyze {post_title}} Market size, forecast the market

4. To classify drivers and challenges for Blue Agave Market

5. To identify Blue Agave Market based on Fleet type, application and regional distribution

6. Competitive study of Blue Agave market players in analyzing the latest trends and business strategies

7. Blue Agave Market report provided concerning price trends and production volume.

The report presents complete information to identify market segments that help to increase the quality of business decision-making based on demand, sales, and product based on application-level analysis and regional level

To Get Instant Access, Purchase Report Here:https://foodnbeveragesmarket.com/purchase-report/?reportId=133995&licenseType=single_user&action=Purchase+Report

Table of ContentsDescribing Detail Research Report :

1. Introduction

2. Research Methodology

3. Report Summary

4. Blue AgaveMarket Overview

Introduction

Drivers

Restraints

Industry Trends

Porters Five Forces Analysis

SWOT Analysis

5. Global Blue AgaveMarket Research, By Product

6. Blue Agave Market Outline, By Applications

7. Blue Agave Market Description, By Regions

8. Competitive Overview

9. Company Profiles

10. Appendix?

AboutFood Beverages Market

Food Beverages Market Research is the terminal where all industrial, commercial and profitmaking venture will get the best research reports of the market in all sectors like automotive, electronics, pharmaceuticals and healthcare, food and beverages etc. The company aims to fulfill market research requirements of both national and international clients. We provide you the important and necessary information to identify and analyze the need of market and the market size.

CONTACT US :

Mr. Benni Johnson

Market.us (Powered By Prudour Pvt. Ltd.)

Email:inquiry@market.us

Address:

420 Lexington Avenue,

Suite 300 New York City,

NY 10170, United States

Tel: +1 718 618 4351

Here is the original post:
Global Blue Agave Market analysis on current and future market trends Up to 2029 - Neptune Pine

Recommendation and review posted by Bethany Smith

Chemical nerve agents are some of the most horrifying tools of war today. The compounds kill by paralyzing the nervous system and have been used in devastating attacks on civilians or soldiers in war zones. And they can appear, albeit in smaller doses, in pesticides used in developing countries, endangering farm workers after prolonged exposure.

For years, researchers have been searching for antidotes or treatments that could save those afflicted by these deadly chemicals. In a paper out today in Science Translational Medicine, a team from the U.S. Army Medical Research Institute of Chemical Defense has announced a potential solution: a gene therapy that grants immunity to the effects of nerve agents like sarin.

Nerve agents are compounds that interfere with a persons nervous system. As the chemicals pass through a body after exposure to skin or through inhalation, they disable an enzyme called acetylcholinesterase thats needed for communication between neurons. The results are devastating: An affected person will involuntarily discharge tears, saliva, urine and feces, experience seizures and paralysis, and rapidly die from asphyxiation.

Scientists have found that that certain enzymes in the body called bioscavengers find and break down the toxic nerve agent molecules in the body, disabling them and preventing harm. In earlier work, the Maryland-based team found that a certain variation of a enzyme made in the liver called PON1 was particularly effective. When injected into a mouse, it granted immunity to nerve agents effects temporarily. But now the team has used a gene therapy to coax the body to make the enzyme, continually, on its own.

In the new study, the team focused on a gene that carries the instructions for the most potent version of the PON1 enzyme, called PON1-IF11. By putting the gene into a virus a common technique used to deliver a gene to a host they were able to successfully introduce PON1-IF11 into mice. After injecting the rodents, just once, with the viral vector containing the gene, the mice became immune to the common nerve agents tabun, sarin, cyclosarin and soman.

The results were encouraging. "[I felt] great satisfaction and excitement," said Venkaiah Betapudi, a molecular cell biologist and first author of the paper, in an email. "[I'm] anxious to take this work to next level and make this modern medicine available to our soldiers."

The immunity lasted for the full 5 months of the study, but in theory, it should last for the lifetime of the animal.

As long as the animal lives, the enzyme is there," says Nageswararao Chilukuri, who leads the research group. "We stopped [the study] at five months after the injection, but if we had measured 6 months, 7 months, 8 months I think it will be there. We just dont have the data to show it.

But Chilukuri emphasizes that were a long way from seeing anything close to a nerve agent vaccine for humans that uses the new technique.

Gene therapy products are only for diseases right now, he explains. We are trying to use this for healthy people. We dont know the long-term safety profile of the viral vectors. We have to be absolutely sure that when we inject a virus, that 50 years from now it will not be toxic or cause any complications.

But when it does come of age, it could have broad applications. "This modern medicine can protect sniffing dogs in the battlefield and TSA and border security operations," says Betapudi.

Luckily, many researchers studying gene therapy more broadly are asking these questions too, so answers may soon emerge regarding the safety of this type of gene therapy.

[Editor's note: This post has been updated to include comments from Venkaiah Betapudi, and to clarify the respective contributions of Nageswararao Chilukuri and Betapudi.]

Originally posted here:
New Gene Therapy In Mice Could Offer Lasting Protection Against Nerve Agents - Discover Magazine

Recommendation and review posted by Bethany Smith

Data further supports Akouoss use of AAVAnc80 technology delivered via intracochlear administration to potentially improve hearing

Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

"Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community," said Greg Robinson, Ph.D., chief scientific officer of Akouos. "The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss."

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005380/en/

Contacts

Katie Engleman, 1ABkatie@1abmedia.com

Read the original:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Yahoo Finance

Recommendation and review posted by Bethany Smith

Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.

Data to be presented at the conference showcase how Decibels drug discovery and translational platform is enabling the development of an array of therapeutic programs, including DB-020 to treat cisplatin-induced ototoxicity and a gene therapy to treat congenital deafness caused by a deficiency in the otoferlin gene. In an invited symposium, Jonathon Whitton, Au.D., Ph.D., director of clinical development, will highlight how Decibel has leveraged its industry-leading, single-cell genomics and bioinformatics capabilities as part of a broader gene therapy platform to optimize therapeutic solutions for hearing loss and balance disorders.

"Over the past year, we have made significant advances in a number of our programs. These developments demonstrate the strength of our unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear," said John Lee, executive vice president, pharmaceutical development.

The Decibel team will have a total of eight posters and presentations during this years meeting.

Podium Presentations

SYMP 12 | Moving Gene Therapies for Hearing Loss into the ClinicDate & Time: Saturday, January 25, 3:15 p.m. PT

PD 35 | Dissecting the Differentiation Fates of Hair Cells in the Vestibular Sensory Epithelia during Mouse Inner Ear Development using Single Cell TranscriptomicsDate & Time: Sunday, January 26, 11:00 a.m. PT

Poster Presentations

PS 60 | Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in Mouse

PS 143 | Multivariate Polygenic Risk Scores Identify Individuals At-Risk for and Protected from Hearing Loss

PS 184 | Natural History and Disease Progression in Two Rodent Models of Monogenic Hearing Loss

PS 463 | DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity

PS 692 | Tailored AAV-based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters

PS 714 | Characterization of an Acute and Cyclic Cisplatin-Induced Hearing Loss in Male Fischer-344 Rats

About Decibel Therapeutics, Inc.Decibel Therapeutics, a development-stage biotechnology company, has established the worlds first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibels lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005232/en/

Contacts

Matthew Corcoran, Ten Bridge Communicationsmcorcoran@tenbridgecommunications.com (617)-866-7350

Read more here:
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference - Yahoo Finance

Recommendation and review posted by Bethany Smith

At the Bio International Convention held last year in Philadelphia, The Discovery Labs announced it was opening 1.6 million square feet of coworking space and collaborative labs for healthcare, life sciences and tech companies out of GlaxoSmithKlinesformer campus in King of Prussia.

About half a year later, nearly all its square footage has been accounted for, Audrey Greenberg, executive managing director of the Discovery Labs, told Technical.ly.

Included is a big get for the region: The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a contract development and manufacturing organization and specialty investment company, the Discovery Labs announced this week.

The Center for Breakthrough Medicines leased 680,000 square feet of Discovery Labs facility to provide pre-clinical through commercial manufacturing of cell and gene therapies, including process development, plasmid DNA, viral vectors, cell banking, cell processing and support testing capabilities.

Its goal is to to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies, Discovery Labs said.

Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive, said Alex Karnal, partner and managing director of Deerfield Management and a board member of the Discovery Labs, in a statement. It is hoped that the Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them.

TheCenter for Breakthrough Medicines has initiated a substantial hiring effort, with plans to hire more than 2,000 team members within the next 30 months in positions like Ph.D. scientists, manufacturing experts, lab technicians and support staff.

Greenberg called the company an end-to-end solution for companies that are looking to manufacture their solutions and products.

There wasnt really space for that to happen, and were in a biotech epicenter, she said. Companies can grow within our space.

An early rendering of The Discovery Labs. (Courtesy image)

First leases within the 1.6 million square feet across campus will likely be taken up by 10 to 20 companies in the first quarter of 2020. Many, including the Center for Breakthrough Medicines, will move into the space in Q3 or Q4 of 2020, after renovations are complete and labs are outfitted to each companys needs.

The campus is also getting a biotech incubator, Unite IQ, which will offer space to emerging life sciences startups with resources needed to initiate business operations. Unite IQ tenants will be able to use the discovery, development, testing and manufacturing capabilities of the Center for Breakthrough Medicines and tech transfer from research lab to large-scale production.

Currently, Philadelphia is home to the only Discovery Labs campus, but the company is looking toward expanding with locations on the West Coast, in Asia and in Europe.

The region is continuously growing as a hub for life sciences, andGreenberg cited King of Prussias proximity to top cell and gene therapy talent, area hospitals and patient pools as important to the Discovery Labs. Also important, she noted, was access to the Philadelphia International Airport (and its supply-chain abilities with cold storage function for transporting cell therapies).

The work is extremely important to Greenberg personally, she said.

Theres an immediacy to this work, in this industry thats working on cures for patients who are dying every day, she said. To me, this work is doing well by doing good.

See the rest here:
A cell and gene therapy development center is taking 680K square feet at KOP's Discovery Labs - Technical.ly

Recommendation and review posted by Bethany Smith

News

Independence Health Group CEO and Chamber of Commerce chairman Dan Hilferty shares his forecast for the growth of the region's bustling health care ecosystem.

Dan Hilferty is the chairman of the Chamber of Commerce for Greater Philadelphia and the CEO of Independence Health Group.

Its been one year since the Chamber of Commerce for Greater Philadelphia, through its CEO Council for Growth and with its partners and collaborators, formally launched the Cell & Gene Therapy and Connected Health Initiative to leverage our regions assets and existing strengths.

My predictions for the initiative and the industry for the coming year are:

Groundbreaking discoveries with origins here have resulted in six FDA-approved therapies since 2017. In 2020, our outstanding research institutions will continue to build on the history of discovery and the recent successes here, leading to more breakthroughs to benefit patients and improve and save lives.

Increased awareness of Greater Philadelphia as a center of innovative excellence in R&D, health care and life sciences will continue to result in an increase in the number of companies locating here as they seek to build out where there is talent, lab space, and research partnership opportunities all close by.

The Chambers Select Greater Philadelphia Council will continue to be a key leader in marketing the region nationally and globally and serving as a connector to welcome these businesses and leaders, and the Chambers CEO Council for Growth is working in 2020 to assess infrastructure needs and identifying opportunities to support this R&D and cell and gene therapy focused growth.

The Greater Philadelphia metro area ranked in the top 10 most active regions in the U.S. for venture funding last year, with venture capital funding in health care more than doubling over the past four years. Recent acquisitions and funding wins speak to the momentum, and we can certainly expect investment growth to continue in 2020.

The region is home to nearly 100 colleges and universities. Through efforts such as the Chambers Regional College and University Presidents Alliance, comprised of higher education leaders focusing on opportunities for collaboration and advocacy, attracting talent to these institutions and retaining talent in our region will continue. The regions robust and growing ecosystem of laboratories, start-ups, manufacturing, and health care technology companies will create more job opportunities which will drive even higher graduate retention.

Connected health technology, through innovative partnerships like our work with Comcast on Quil, is another area in which our region is creating breakthroughs, as technology gives patients new tools and experiences to manage their care. We can expect new developments in this quick-moving industry.

Daniel J. Hilferty is chairman of the Chamber of Commerce for Greater Philadelphia chief executive officer of Independence Health Group, parent of Independence Blue Cross.

Excerpt from:
5 Predictions for Philadelphia's Cell and Gene Therapy Sector in 2020 - Philadelphia magazine

Recommendation and review posted by Bethany Smith

Teens with obesity and polycystic ovary syndrome (PCOS) have more unhealthy gut bacteria, suggesting the microbiome may play a role in the disorder, according to new research published in the Endocrine Societys Journal of Clinical Endocrinology & Metabolism.PCOS is complicated endocrine disorder affecting 6 percent to 18 percent of women of reproductive age and work in adult women indicates that changes in bacteria be involved. The hormone disorder is characterized by elevated testosterone levels in the blood that cause acne, excess hair growth and irregular periods. Teens with PCOS often also struggle with obesity and have a higher risk for type 2 diabetes, infertility, and depression.

We found that in adolescents with PCOS and obesity, the bacterial profile (microbiome) from stool has more unhealthy bacteria compared to teens without PCOS, said the studys corresponding author, Melanie Cree Green, M.D., Ph.D., of Childrens Hospital Colorado in Aurora, Colo. The unhealthy bacteria related to higher testosterone concentrations and markers of metabolic complications.

The researchers studied 58 teens with obesity and found that girls with PCOS have an altered gut microbiome compared to those without the condition. These girls had more unhealthy bacteria in their stool which was related to higher testosterone levels and other markers of metabolic syndrome, such as higher blood pressure, liver inflammation and plasma triglycerides.

The gut microbiome may play a role in PCOS and its related metabolic complications, and these changes can be found in teenagers who are early in the course of the condition, Green said.ReferenceJobira et al. (2020) Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. Journal of Clinical Endocrinology & Metabolism. DOI: https://doi.org/10.1210/clinem/dgz263

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
"Unhealthy" Gut Microbiome Linked to PCOS and Obesity in Teens - Technology Networks

Recommendation and review posted by Bethany Smith

The first symposium of the South West Brain Tumour Centre was held on Thursday at Derriford Hospital in Plymouth. During a fascinating and very well attended event, topics covered included the mechanism of tumour development, new drug targets, new biomarkers and brain tumour imaging. The South West Brain Tumour centre is of course one of the UK Centres of Excellence funded by Brain Tumour Research.

A really big cancer wide story this week is here Immune discovery 'may treat all cancer' applicable to some solid tumours but not yet brain it really shows the direction of travel toward immunotherapy I have recommended this book before but if interested please do read The Breakthrough by Charles Graeber it is available on Amazon and you can read reviews here - http://www.charlesgraeber.com.Researchers uncover novel drug target for glioblastoma by revealing a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. This pathway shows that glioma stem cells ability to access key nutrients in their surrounding microenvironment is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma.

An intelligent molecule could significantly extend the lives of patients with glioblastoma, research finds. The molecule, called ZR2002, which can be administered orally and is capable of penetrating the blood-brain barrier, could delay the multiplication of glioblastoma stem cells resistant to standard treatment. According to scientists in the Metabolic Disorders and Complications Program at the Research Institute of the McGill University Health Centre (RI-MUHC) the ZR2002 molecule is designed to kill two birds with one stone: on top of attacking the tumour, it destroys its defence system.

Researchers find clues to drug resistance in medulloblastoma subtype.US scientists have identified specific types of cells that cause targeted treatment to fail in a subtype of medulloblastoma. They found while the majority of cells responded to treatment, diverse populations within the tumour continue to grow leadingto treatment resistance. They concluded that the diversity of cells within tumours allow them to become rapidly resistant to precisely targeted treatments," and that due to this tumour cell diversity, molecularly precise therapies should be used in combinations to be effective."

Nanoparticles deliver 'suicide gene' therapy to paediatric brain tumours growing in mice So-called "suicide genes" have been studied and used in cancer treatments for more than 25 years. Researchers report here that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a ''suicide gene'' to paediatric brain tumour cells implanted in the brains of mice.

According to a study that uncovers an unexpected connection between gliomas and neurodegenerative diseases a protein typically associated with neurodegenerative diseases like Alzheimers might help scientists explore how gliomas become so aggressive. The new study, in mouse models and human brain tumour tissues, was published in Science Translational Medicine and found a significant expression of the protein TAU in glioma cells, especially in those patients with better prognoses. Patients with glioma are given a better prognosis when their tumour expresses a mutation in a gene called isocitrate dehydrogenase 1 (IDH1). In this international collaborative study led by the Instituto de Salud Carlos III-UFIEC in Madrid, Spain, those IDHI mutations stimulated the expression of TAU. Then, the presence of TAU acted as a brake for the formation of new blood vessels, which are necessary for the aggressive behaviour of the tumours.

'Innovative research award' helps Colorado scientists block brain cancer escape routes Cancers used to be defined by where they grow in the body - lung cancer, skin cancer, brain cancer, etc. But work in recent decades has shown that cancers sharing specific genetic changes may have more in common than cancers that happen to grow in an area of the body. For example, lung cancers, skin cancers, and brain cancers may all be caused by mutation in a gene called BRAF. Drugs targeting BRAF have changed the treatment landscape for melanoma, an aggressive form of skin cancer, and are also in use against lung cancers and brain cancers with BRAF mutations. It is really worth clicking through to read more on this and the ultimate goal of identifying new potential targets for combination therapy and new agents that could be added to BRAF inhibiting drugs in brain cancer to keep the cancer from developing resistance.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Go here to read the rest:
Weekly pick of brain tumour research news from around the world - Brain Tumour Research

Recommendation and review posted by Bethany Smith

The global market for Cancer Therapies is projected to reach US$220. 5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease.

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original:
Global Cancer Therapies Industry - Yahoo Finance

Recommendation and review posted by Bethany Smith

Newark, NJ, Jan. 24, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal beauty and personal care products market is expected to grow from USD 493.34 billion in 2018 to USD 756.63 billion by 2026, at a CAGR of 5.81% during the forecast period 2019-2026.

Beauty and personal care products are used to enhance the appearance of the face or fragrance and texture of the body. Many beauty products are designed for applying to the face and body. They are generally mixtures of chemical compounds derived from natural sources or maybe synthetic or artificial. Nowadays, many companies are producing natural and organic beauty and personal care products, with the increasing consumer concern over chemical usage in beauty products. In addition to this, an increasing trend of personalization and customization of beauty and personal care products is expected to offer considerable opportunities in the market. Moreover, innovation in packaging of beauty products is further boosting the growth of the market, during the forecast period 20192026.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/407144/request-sample

Global Beauty and Personal Care Product Market Key Findings:

Browse full report with TOC athttps://www.fiormarkets.com/report/beauty-and-personal-care-products-market-by-product-407144.html

About the report:

The global beauty and personal care product market is analysed on the basis of value (USD Billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Know More Market Research Reports and Industry Analysis, Visit our Associate Website: https://marketandresearch.bizRelated Reports

Global Breast Cancer Liquid Biopsy Market - https://www.fiormarkets.com/report/global-breast-cancer-liquid-biopsy-market-by-circulating-376049.htmlGlobal Cell Therapy Technologies Market - https://www.fiormarkets.com/report/global-cell-therapy-technologies-market-by-product-consumables-376050.htmlGlobal Gene Therapy Market - https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.htmlGlobal Health Intelligent Virtual Assistant Market - https://www.fiormarkets.com/report/global-health-intelligent-virtual-assistant-market-by-products-376053.html

More:
Global Beauty and Personal Care Product Market is Expected to Reach USD 756.63 Billion by 2026 : Fior Markets - GlobeNewswire

Recommendation and review posted by Bethany Smith

The Fulton County Health Department has scheduled the following health clinics and services.

CANTON The Fulton County Health Department has scheduled the following health clinics and services. Please call the number listed with each service for an appointment or more information.

Maternal child health: Health screenings, WIC nutrition education and supplemental food coupons for women, infants and children. To make an appointment or for more information call 647-1134 (ext. 254). For Astoria clinic appointments call 329-2922.

Canton - Clinic - Monday, Jan 27 - 8-4 - Appt needed

Canton - WIC Nutrition Education - Tuesday, Jan 28 - 8-4 - Appt needed

Astoria - Clinic, WIC Nutrition Educ. - Wednesday, Jan 29 - 9-3 - Appt needed

Canton - Clinic - Thursday, Jan 30 - 8-4 - Appt needed

Adult Health Immunizations: Various vaccines are available. There is a fee for immunization administration. Medicaid cards are accepted. To make an appointment or for more information call 647-1134 (ext. 254).

Other times available by special arrangement at Canton, Cuba and Astoria.

Blood Lead Screening: Blood lead screenings are available for children ages one to six years. A fee is based on income. To make an appointment or for more information call 647-1134 (ext. 254). For Astoria appointments call 329-2922.

Family Planning: Confidential family planning services are available by appointment at the Canton office for families and males of child-bearing age. Services provided include physical exams, pap smears, sexually transmitted disease testing, contraceptive methods, pregnancy testing, education and counseling. Services are available to individuals of all income levels. Fees are based on a sliding fee scale with services provided at no charge to many clients. Medicaid and many insurances are accepted. After hours appointments are available. To make an appointment or for more information call the 647-1134 (ext. 244). *Program funding includes a grant from the US DHHS Title X.

Pregnancy testing: Confidential urine pregnancy testing is available at the Canton and Astoria offices. This service is available to females of all income levels. A nominal fee is charged. No appointment is needed. A first morning urine specimen should be collected for optimal testing and brought to the health department. Services are provided on a walk-in basis on the following days each week:

Canton: Every Wednesday & Thursday, 8-3:30 (for more information call 647-1134 ext. 244)

Astoria: Every Wednesday, 9-2:30 (for more information call 329-2922)

Womens Health: A womens clinic for pap tests, clinical breast examinations and vaginal examinations is available by appointment. There is a nominal fee for this service. Medicaid cards are accepted. Financial assistance is available for a mammogram. Cardiovascular screenings may be available to age and income eligible women. To make an appointment or for more information call 647-1134 (ext. 244).

Mammograms: Age and income eligible women may receive mammograms at no charge. Speakers are available to provide information to clubs and organizations. For more information or to apply for financial assistance, call 647-1134 (ext. 254).

Mens Health: Prostate specific antigen (PSA) blood tests are available for men for a fee. To make an appointment or for more information call 647-1134 (ext. 224).

Canton - Clinic - Monday, Jan 27 - 8-12 - Appt needed

Sexually Transmitted Disease (STD) Clinic: Confidential STD and HIV testing services are available by appointment to males and females at the Canton office. Services include physical exams to identify STDs, a variety of STD testing, HIV testing, education, counseling, medications and condoms. There is a nominal fee for services. Services are available to individuals of all income levels. Medicaid cards are accepted. To make an appointment or for more information call 746-1134 (ext. 224).

HIV Testing and Counseling: Confidential HIV testing and counseling services are available by appointment through the sexually transmitted disease (STD) clinic at the Canton office. To make an appointment or for more information call 647-1134 (ext. 224).

Tuberculosis (TB) Testing: TB skin tests are available at no charge by appointment. To make an appointment or for more information call 647-1134 (ext. 254).

Blood Pressure Screenings: The Fulton County Health Department provides blood pressure screenings at no charge on a walk-in basis during the following times:

Canton - Screening - Monday, Jan 27 - 8-5 - Walk in/Room 108

Cuba - Screening - Monday, Jan 27 - 8-12 - Walk in

Astoria - Screening - Wednesday, Jan 29 - 9-12 - Walk in

Health Watch Wellness Program: The Health Watch Program provides low cost lab services. Through this program adults can obtain venous blood draws for a variety of blood tests. Blood tests offered without a doctors order Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC), Lipid Panel, Prostate Specific Antigen (PSA) test, Hepatitis C test, and Thyroid Stimulating Hormone (TSH). A wide variety of blood tests are also available with a doctors order. There is a charge at the time of service. To make an appointment or for more information call 647-1134 (ext. 254).

Canton - Clinic - Monday, Jan 27 - 8-12 - Appt needed

Dental Services: The Dental Center offers a variety of basic dental services to children and adults. An appointment is needed. Medicaid and Kid Care cards are accepted. To make an appointment or for more information call 647-1134 (ext. 292).

Read the original post:
Health Department announces services for the week of Jan 27 - Teutopolis Press-Dieterich Gazette

Recommendation and review posted by Bethany Smith

In the predawn darkness, you can see an eerie red glow shining from the windows of the Hudson, Wis., home of Thaddeus Owen and his fiance, Heidi Sime.

The couple are awake, having slept in their Faraday cage a canopy over their bed that blocks electromagnetic fields like the Wi-Fi signals or radiation from cellphone towers, which they believe are harmful.

Their primal sleeping environment also has special pads under the bed that are supposed to mimic the effect of sleeping on the ground under the influence of the Earths magnetic field, thus combating Magnetic Field Deficiency Syndrome.

Their house is bathed in red light because they think white incandescent, LED and fluorescent lighting robs them of sleep-regulating melatonin hormones. They wear special sunglasses indoors for the same reason, blocking the blue light from computers, cellphones or televisions when its dark outside.

Their morning routine includes yoga in a shielded, infrared sauna designed to create an EMF-free ancestral space, and putting tiny spoonfuls of bitter white powders under their tongues. These are nootropics, so-called smart drugs, which are supposed to improve focus, mood or memory.

When day breaks, they go out in their yard and face the rising sun Thaddeus in shorts and no shirt, Heidi in a sports bra and yoga pants doing Qigong in the snow and 25-degree air.

Getting early-morning sunlight, they believe, will correctly set the circadian rhythm of their bodies. Exposing their skin to the freezing temperatures, they hope, will help release human growth hormone, stimulate their immune system and trigger the body to burn fat to heat itself.

Forget Blue Zones. This is what your morning looks like if youre biohacking your way to an optimal you.

Biohacking is a DIY biology movement that started in Silicon Valley by people who want to boost productivity and human performance and engineer away aging and ordinary life spans. Think of it as high-tech tinkering, but instead of trying to create a better phone, biohackers are trying to upgrade to a faster, smarter, longer lasting, enhanced version of themselves.

Owen, 44, describes it as a journey of self-experimentation, using practices that are not talked about by mainstream media and your family doctor. His aim is to combine the latest technology and science with ancient knowledge to modify his environment, inside and out.

My entire goal is to basically age in reverse, he said.

Aiming for supernormal

Owen, who is from New York, studied chemical engineering in college. He worked for Procter & Gamble, helping to create beauty care products, and for pharmaceutical firms, developing manufacturing processes.

Now he works from home, managing worldwide product regulations in the sustainability department for office furniture company Herman Miller. But he moonlights as a biohacking guru.

He started a Twin Cities biohacking Meetup group that organizes weekly cold-water immersions at Cedar Lake in Minneapolis. Hes given a TEDx talk urging audience members to wear blue-light-blocking glasses indoors at night.

Hes helping to organize a Cold Thermogenesis and Heat Shock retreat at the end of next month in Pequot Lakes, Minn., where 50 people will pay up to $2,300 to spend four days going on shiver walks, drinking Bulletproof coffee and plunging into ice water.

He founded the website primalhacker.com and he and the 45-year-old Sime (who also goes by the name Tomorrow) run a website called thaddeustomorrow.com, where they market biohacking products like red light panels, a baby blanket that blocks EMF radiation and a $5,499 Faraday cage sauna thats the same type used by Twitter founder Jack Dorsey.

Owen said he relies on tons of research to support avoiding blue light at night and the healing properties of the early morning sun.

The Harvard Health Letter, for example, said that blue light from devices, LED and compact fluorescent bulbs can throw off the bodys circadian rhythm, affect sleep and might contribute to cancer, diabetes, heart disease and obesity. Some studies have shown that exposing people to cold temperatures burns calories and repeated cold-water immersions might stimulate the immune system.

And those infrared saunas? They dont appear to be harmful and maybe they do some good, according to Dr. Brent Bauer, an internal medicine expert at the Mayo Clinic.

But being healthy really doesnt need to be that complicated, according to Dr. Michael Joyner, a human performance specialist at the Mayo Clinic.

All these things sound great, Joyner said of the biohacks. Theres a ring of what I call bioplausibility to them.

But Joyner said its often hard to find evidence that biohacking practices actually work and that most Americans would be healthier if they just followed basic advice.

You need to go for a walk, not smoke, not drink too much, dont eat too much, he said.

But Owens goal is not to be merely healthy.

I want my biology to be shifted to that supernormal range, where Im optimally healthy, he said.

Moving into the mainstream?

When he started biohacking about 12 years ago, Owens goal was to improve his sleep. As a competitive athlete, he was fit, but he had problems with anxiety and insomnia.

So he started wearing special glasses to block blue light. His co-workers used to think he was odd. Now Owens company is asking him for advice on what kind of lighting should be used in work settings to keep employees healthy. And his sleep and anxiety problems have gone away.

I went from being the weird guy to being consulted, he said.

We all sort of watch what he does, said Gabe Wing, director of sustainability at Herman Miller and Owens boss. Wing said Owen has influenced some co-workers to try blue-light-blocking tools. But no one at the Michigan-based company is going outside shirtless in the winter.

Still, more people are biohacking. When Owen first got into it, he didnt know of any other biohackers in the Twin Cities. Now there are more than 500 people in the Biohackers Twin Cities Meetup group.

Susan Eiden regularly gets advice from Owen. The Minneapolis resident said using red lights at home has drawn comments from neighbors, but the lights combined with blue-blocking glasses and turning off the Wi-Fi at night have improved her sleep.

While many biohacks seem odd now, Owen is convinced that some of them will become common practices.

This whole blue light thing, its not going away, he said. More research comes out every day and its becoming more mainstream. And using nootropics is growing bigger and bigger every day, he said.

Owen takes supplements, some of which are considered prescription drugs in Europe and Russia, like phenylpiracetam, which is said to have boosted stamina among Soviet cosmonauts. Other preclinical compounds he and Sime use are in a regulatory gray area in the United States. Nootropic developers give them supplements that arent on the market yet because theyre biohacking influencers.

Were like lab rats. They send us stuff. We try it out, Sime said.

All for longevity

Owen and Sime have five of their children, ages 8 to 17, living with them. The kids wear blue-light-blocking glasses when they watch TV, but theyre OK with it, the couple said. Some of the kids have made videos or given talks to peers about the benefits of the glasses.

I think cellphone radiation is going to be the new lead, asbestos and smoking, said Owen, who turns his Wi-Fi off at night, keeps his cellphone in a special Faraday pouch when he sleeps and sometimes wears radiation-proof underwear.

(The National Institute of Environmental Health Sciences says scientific evidence has not conclusively linked cellphone use with any adverse human health problems, although scientists admit that more research is needed.)

Owens diet isnt typical, either.

Hes been a vegan and a vegetarian. Now he eats what he describes as a local, seasonal diet: local vegetables, fruits, nuts and honey during the growing season. Thats followed by a high-fat, low-carb ketogenic diet in late fall and early winter. Then an all-carnivore diet in late winter, including animals hes raised at a friends farm.

One of the few white light bulbs he has in his house is pointed at the stove because in red light, its hard to tell if meat is cooked.

He also consumes ceremonial grade cacao, coffee with collagen peptides and chocolate ghee and homemade sauerkraut thats fermented and subjected to special music that has the frequency of love.

Those are living microbes, so I infused them with a love frequency to make them happy and healthy, said Owen, who has a masters degree in holistic nutrition.

While he used to do marathons and triathlons, he now exercises for longevity rather than competition, with high-intensity training, weights, racquetball and cross-country skiing.

If its too cold to be barefoot when he goes out in the morning, hell put special straps on his boots to create a conductive connection between his body and the Earth.

Its a practice called grounding or Earthing thats supposed to allow electrons to pass between the Earth and his body to reduce inflammation and neutralize free radicals. Gwyneth Paltrow swears by it, according to an article on goop.com.

Owen doesnt have a particular longevity goal, unlike biohacker and Bulletproof Coffee founder Dave Asprey, who has said he wants to live to at least 180.

Owen just wants to be healthy and independent for as long as he lives.

I want to maximize the health of my biology to what its capable of, he said. I want to live the best life that I can. I want to be happy. And I want to have a body and a mind that does the things I want them to do.

More:
Sleep cages and ice baths: The extreme lifestyle of local biohackers - Minneapolis Star Tribune

Recommendation and review posted by Bethany Smith

Between 2000 and 2012, the Department of Veterans Affairs reported a 327% increase in anxiety disorders among military members. A recent study suggests that this may be due to the discovery of a so-called "worry gene." Researchers from Yale University in New Haven, Connecticut, and the University of California in San Diego analyzed the genes of 200,000 U.S. veterans and identified six genetic variants linked to anxiety a discovery that may help explain why anxiety and depression often go hand in hand.

The study authors hailed their finding as "the richest set of results for the genetic basis of anxiety to date." But leading psychologists say that while genes may load the gun, it's most often environment that pulls the trigger on mental health disorders.

According to Mental Health First Aid, 20 veterans die by suicide each day. Over 30% of active duty and military personnel deployed in Iraq and Afghanistan have a mental health problem requiring treatment, but only half of these returning veterans receive the care they need.

"We should spend as much money on helping these veterans re-enter their civilian lives as we do in training them for the military," Dr. Terry Lyles, Ph.D., an internationally recognized expert on dealing with trauma and stress, tells Newsmax. "The study points the finger at genetics on why our military personnel have mental health issues. However, we basically all have the same genetic patterns but when threatened with violence, danger, and combat stress, we release levels of cortisol, the stress hormone, that drains our bodies of the natural resources to deal with that constant bombardment.

"Cortisol literally eats serotonin, the hormone that helps regulate mood and social behavior. So, when these veterans are subjected to constant threats, improper nutrition, lack of sleep, and sunlight it's no wonder they become rewired to exhibit anxiety and depression."

Lyles, known as America's "Stress Coach," uses highly specialized techniques to help veterans and other individuals such as the rescue workers at Ground Zero and those in the tsunami-torn area in Asia to help channel mental negativity and chaos into more productive and positive pathways.

Dr. Lois Mueller, a clinical psychologist from Tampa who worked at the U.S, Department of Veterans Affairs, Outpatient Clinic for 10 years, tells Newsmax, that people with a genetic predisposition toward anxiety will have a 10-fold increased risk of developing a mental disorder when being placed in a combat situation where people around you are wounded or dying.

"Whatever they came with genetically was certainly affected by their environment," she says. "The proof of impact of combat would be to compare vets before being in the military and five years after combat. Don't forget, a lot more were traumatized not only by combat itself but also by associated military duties such as picking up and bagging bodies or delivering the folded flags to mothers here in the States.

"My experience with vets with PSTD is very often people who were calm and worry-free prior to combat ended up anxious and fearful after leaving the military. Early treatment can make a difference but length of exposure to combat can make it very difficult to eliminate the problem. We are still learning about treatment techniques."

2020 NewsmaxHealth. All rights reserved.

Read more:
Solving Depression and Anxiety in Veterans - Newsmax

Recommendation and review posted by Bethany Smith

In the largest genetics study of its kind to date, scientists have identified 102 genes associated with the risk for autism spectrum disorder (ASD).

Researchers also gained further insight into which of these genes are associated with both ASD and other disorders that cause intellectual disability and developmental delay.

For the study, an international team of researchers analyzed more than 35,000 participant samples, including almost 12,000 from people with ASD.

Researchers used a genetic technique called exome sequencing, which looks at all the regions of a persons genetic information or genome that are translated into proteins. This testing can pick up rare genetic mutations that might not show up with other methods.

Dr. Lonnie Zwaigenbaum, a professor in the Department of Pediatrics and the Stollery Childrens Hospital Foundation Chair in Autism at the University of Alberta, called this an exciting study, both for the sophisticated methods used and the large sample size.

These enabled researchers to identify a larger number of genes than ever before, which gives insight into how those genes operate and how they might increase the risk of ASD, said Zwaigenbaum, who wasnt involved in the research.

The study results were published January 23 in the journal Cell.

ASD is a group of neurological and developmental conditions that affect communication and behavior. Theres wide variation in the type and severity of symptoms in people with ASD.

Scientists believe that both genes and environment are involved in the development of ASD, with genetics playing a big part.

We know that inherited and unique mutations in the genome are a major source of risk for developing ASD, but specific causes of ASD are not yet well understood, said Lori J. Warner, PhD, director of the Center for Human Development and Ted Lindsay Foundation HOPE Center at Beaumont Childrens Hospital in Royal Oak, Michigan, who wasnt involved in the study.

Although environmental factors play some role in ASD, scientific studies have found that theres no link between receiving vaccines and developing ASD.

The new study marks an important step forward in scientists understanding of the genetic basis of ASD.

Researchers identified both inherited genetic mutations and de novo mutations ones that occur spontaneously when an egg or sperm form.

They also found that the ASD genes identified in the study can affect brain development or brain function. And they showed that two major types of nerve cells can be affected in ASD.

Of the 102 genes identified in the study, 49 were associated with other developmental delays.

Some genes appear connected to the development of ASD, whereas others may increase risk for ASD plus severe neurodevelopmental disorder, said Warner. We dont yet understand fully this process, but differentiating ASD from other disorders is important for effective treatment.

Zwaigenbaum said the overlap between ASD and other neurodevelopmental disorders fits with previous research.

This study reinforces that there are many genes that may have some role in autism vulnerability, but that also have a broader role in early brain development, said Zwaigenbaum.

These genes have a broader expression in terms of developmental abilities and challenges of the affected individual.

While scientists now understand ASD better as a result of this study, this kind of research also points toward better ways to help children with ASD.

The greatest benefit of studies of this type is helping researchers, families, and interventionists better understand how genetic factors actually function in the developing brain and body of the individual, said Warner, so that treatments can be developed to ameliorate or completely block the disruptive changes that lead to disorders such as ASD.

But Zwaigenbaum cautions that the results of the study will not lead to clinical benefits right away.

Theres a lot of translational work that would still need to happen in order to assess whether the findings from this study will directly inform assessment, diagnosis, or treatment, he said.

Still, he said the results provide direction for future research into potential biological treatments, as well as genetic tests that could allow earlier diagnosis of ASD.

Warner said there are medications currently approved for use in children with ASD, but they address symptoms like agitation or anxiety, rather than the core social or behavioral deficits of ASD.

Early diagnosis is another goal of ASD research, because the sooner children are identified and appropriately assessed, the sooner families can receive needed supports, said Warner.

But ASD is a complex condition, so genetic diagnosis isnt always straightforward.

Although studies like this continue to expand our appreciation for the increasing number of genes associated with ASD, the reality is that a genetic cause is seldom identified in most children with ASD even with the most sophisticated genetic testing, said Andrew Adesman, MD, chief of Developmental & Behavioral Pediatrics at Cohen Childrens Medical Center in Queens, New York, who wasnt involved in the study.

But he said theres still value in parents of a child with ASD seeking out genetic testing, especially as genetic technologies advance.

There have been steady gains in terms of the diagnostic yield of genetic testing, said Adesman. For this reason, parents of children with ASD may wish to discuss with their pediatrician whether their child should have the newer genetic tests done.

In the absence of a simple test for ASD, there are still things parents can do for their children.

The single most important things families and healthcare providers can do is to be aware of the risk factors and early signs and symptoms of autism, and get connected with needed services as soon as possible, said Warner.

Continue reading here:
What Causes Autism? Researchers ID 102 Genes Linked to Condition - Healthline

Recommendation and review posted by Bethany Smith

Thursday, January 23, 2020

Florida could be the first state to deny life and long-term care insurers access to genetic test results. Under a new bill titled Genetic Information for Insurance Purposes (HB 1189), life insurers and long-term care insurers are prohibited from canceling, limiting, or denying coverage, or establishing differentials in premium rates based on genetic information. In addition, HB 1189 would prevent life insurers and long-term care insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or actions relating to genetic testing in any manner for any insurance purposes.

On Jan. 16, the Florida House Health & Human Services Committee passed HB 1189 without any debate. The bill is now being reviewed by the Commerce Committee, which will have to clear the bill before it would be ready to go to the full House.

HB 1189 is sponsored by Representative Chris Sprowls, the incoming Speaker-designate. It is the only bill he has filed this year. In the Senate, the bill is sponsored by Kelli Stargel, who is part of Senate leadership. Given HB 1189s sponsors, the issue will likely be a high profile one, and will have a good chance of passing in the next year or two.

Existing federal law, the Genetic Information Nondiscrimination Act (GINA), protects Americans from discrimination in health insurance, employment decisions, and employee benefit decisions on the basis of genetic information. Under GINA, U.S. insurance companies and health plans (including both group and individual insurers, as well as federally regulated plans) are prohibited from:

looking at predictive genetic information or genetic services before enrollment;

requesting or requiring that individuals or their family members take a genetic test;

restricting enrollment based on genetic information;

changing premiums based on genetic information.

GINA, however, does not cover life, long-term care, or disability insurance providers. As a result, those companies can ask about health, family history of disease, or genetic information, and reject those that are deemed too risky.

2020 Greenberg Traurig, LLP. All rights reserved.

Read more from the original source:
Genetic Non-Discrimination Bill Advances in Florida - The National Law Review

Recommendation and review posted by Bethany Smith

As the threats of cyberattacks now loom large in the aftermath of recent U.S. tensions in the Middle East, caution is needed with recreational use of genetic testing.

Just a month ago, on Dec. 20, a memorandum advising U.S. military personnel to refrain from the purchase or use of direct-to-consumer (DTC) genetic testing services was sent to a wide Defense Department distribution list. This memo came from the U.S. Under Secretary of Defense for Intelligence Joseph D. Kernan and Assistant Secretary of Defense for Manpower and Reserve Affairs James N. Stewart. This was a wise move, as Kernan and Stewart reminded their audience that this largely unregulated DTC genetic testing industry poses potential risks to individual privacy and to national security that could affect military operational readiness.

Privacy considerations and readiness issues are raised by DTC genetic testing of military service members, and major security concerns are at hand.

We already know that foreign governments are exploiting various surveillance methods, including DNA-typing, for monitoring individuals without their consent. There are well-known national security concerns that biological weapons can target specific groups or individuals who are genetically vulnerable to the effects of weaponized pathogens or other diseases. Besides these concerns, large-scale DNA typing affords use of genetic data for individualized identification, permits identification of unexpected parentage and family relationships, and exploits the ability to estimate bio-geographic ancestry.

While some of these genetic data generated are useful for various recreational purposes and for certain forensic investigations, unauthorized hacking of the data on military members could compromise national security for covert operators and for unit cohesion and mission readiness.

Two facts about genetic testing in military health settings are not well-appreciated.

First, protections of the Genetic Information Nondiscrimination Act (aka GINA), signed into law by President George W. Bush, do not apply to the military. While there are some policies in place to deal with genetic health information for service members, some genetic testing results, for example the finding of sickle cell trait, can place restrictions on some members with aviation specialties.

Get the military's most comprehensive news and information every morning

(please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Subscribe

By giving us your email, you are opting in to the Early Bird Brief.

Second, U.S. DoD policies (i.e., DodI 6025.19) require service members to report (any) medical and health issues that may affect their individual readiness to deploy to serve on active status and to report any significant health information up the chain-of-command.

These realities present conundrums for those serving on active status in the military. This is due to the large amount of genetic data that are assessed by the DNA companies, often then shared electronically with other companies from the saliva or cheek swab samples they collect.

Depending on the testing kit and service requested by the consumer, genetic disease carrier state and health risk information is often communicated, but not necessarily confirmed or validated by another method, nor are new tests necessarily even reviewed by the FDA before being offered. Such testing results, if affecting a large fraction of those serving in a military unit be it a squad, platoon or company could easily interfere with critical missions if the purported results require verification by followup testing or clinical evaluation of the service member.

These matters concern all of us. Our passion for freedom requires us to walk the long and winding road to digital freedom. We must more carefully examine the commercial interests of DTC companies and the security of the genetic data they control as we balance interests in privacy of our service members and our national security, too often threatened and those of privacy rights, too often denied.

Frederick R. Bieber, Ph.D., is a forensic DNA-expert and member of the faculty of medicine at Harvard University. He served as a U.S. Army Reserve officer at the U.S. DoD DNA-Identification Laboratory (AFDIL) in Rockville, Maryland, the Dover AFB Mortuary, and at the U.S. Army Criminal Investigation Laboratory (USACIL) at Fort Gillem, Georgia.

Editors note: This is an Op-Ed and as such, the opinions expressed are those of the author. If you would like to respond, or have an editorial of your own you would like to submit, please contact Military Times managing editor Howard Altman, haltman@militarytimes.com.

More here:
Digital freedom and DNA: Caution advised on the road ahead - Military Times

Recommendation and review posted by Bethany Smith

Lets say, for the holidays, you got a kit from Ancestry.com, 23andMe or a similar company to send in your DNA (aka your spit) and discover your roots as well as your personalized health report.

You spit, you send it off, and youre starting to get the results back.

And in that personalized health report, theres an indication for an increased cancer risk, or theres no indication of an increased cancer risk ... now what? Can these reports be believed? Should you go running to find the nearest doctor to prevent your impending death?

Gayle Patel, a certified genetic counselor and the director of the Genetic Risk Evaluation and Testing Program at Texas Oncology, wants people to know these tests arent looking at the whole genome. Theres a limit to what it can do, she says, but they might come up with some interesting health traits, as well as your long-lost ancestors.

Some of the mysteries they can solve, such as whether there is a genetic reason you prefer chocolate or vanilla ice cream, can be fun, she says. But its not telling the whole story.

If results from one of these tests show an increased risk for something, she recommends bringing that information to your doctor at your next appointment. Its not that you have a disease but that you may have an increased risk, she says.

Your doctor will want to assess what the risk is, how accurate it is and what preventative steps you might want to take, she says.

These boxed ancestry/DNA tests dont have the experts who can personalize the test for you based on your medical and family histories. They also dont have a person explain it to you and make a plan for you.

It can be difficult and scary, she says, to get these results. None of this is destiny or fate. Its talking to you about personalizing your medical care.

Her bigger concern is not that these tests are going to find a risk; its that they wont find a risk and you will think you are fine and not do the usual preventative treatments or recommended screenings.

For example, about a year ago, 23andMe added some of the BRCA mutations to what it looks for. BRCA mutations indicate a risk for breast cancer and ovarian cancer. Patel says this test now is looking at only three of the mutations when there are thousands. Weve had patients who think they have tested negative for that type of cancer when its not true.

Instead, based on personal medical history and family history, shell recommend doing a medical-grade test in an office that specializes in genetic testing to get a comprehensive look at all types of cancer risks.

Were either going to confirm or make sure were not missing something else that can be just as important, Patel says.

Medical testing has gone down in price, and this kind of genetic testing now can be done for about $250, she says, which is about the price of the 23andMe or Ancestry.com kit that includes health DNA. Often, based on medical history, insurance will cover the medical tests.

Patel also wants folks to realize that only about 5% to 10% of all cancers have a known genetic component. Of course, it depends on the type of cancer. Ovarian cancer has about a 23% genetic link, she says, but lung and cervical cancer tend to be more environmental and less likely to be genetic.

New gene mutations are being discovered all the time as more and more data is collected, and what genetics counselors can test for changes all the time, too.

Patel also recommends reading the fine print of where your DNA data is being stored by these companies. Who owns the data, and how is the data being shared? It might be going to a database accessed by pharmaceutical companies for research on new cancer treatments, or it might be on an open database accessible to anyone. As long as they are informed and educated, she says, then these tests are OK. Learn before they spit.

As well, be prepared for the results you might get, such as a long-lost brother or that your father isnt your biological father. It could be one of these surprises that could change how you think about your family, she says.

More:
What 23andMe, Ancestry.com kits arent telling you about your health risks - austin360

Recommendation and review posted by Bethany Smith

Researchers have identifiedmore than 100 genes associated with autism in the largest genetic-sequencing study to date that could help shed light on the causes of the condition.

In a study published Thursday in the peer-reviewed journal Cell, a team of researchers identified 102 genes associated with the risk of autism spectrum disorder (ASD), using samples from more than 35,000 participants, 12,000 of which had autism. They were able to study genes that were inheritedas well as those that occurred spontaneously when the egg or sperm is formed.

The study shows progress toward teasing apart genes associated with ASD from those associated with intellectual disability and developmental delay, conditions that often overlap.

Of the 102 genes associated with ASD risk, 49 were also associated with other developmental delays.

With these identified genes we can begin to understand what brain changes underlie ASD and begin to consider novel treatment approaches, Joseph Buxbaum, the director of the Seaver Autism Center for Research and Treatment at Mount Sinai, said in a statement.

ASDis a developmental disorder that affects communication and behavior, and although autism can be diagnosed at any age, it is said to be a developmental disorder because symptoms generally appear in the first two years of life.

The Centers for Disease Control and Preventionestimates that about 1 in 59 children has been identified with ASD.

Researchers said the results were encouraging as genetic testing could increase the likelihood of figuring out the cause of some childrens autism.

Through our genetic analyses, we discovered that its not just one major class of cells implicated in autism, but rather that many disruptions in brain development and in neuronal function can lead to autism, Buxbaum said. We now have specific, powerful tools that help us understand those underpinnings, and new drugs will be developed based on our newfound understanding of the molecular bases of autism.

Visit link:
Researchers identify more than 100 genes associated with autism - The Hill

Recommendation and review posted by Bethany Smith